血糖和丙酮等化验值只是身体策略改变的迹象，而不是原因；没有必要测量血糖或血压。
原始表述
انا مش عايز قياس لحاجه لا ضغط ولا سكر ولا الكلام ده كله
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
血糖和丙酮等化验值只是身体策略改变的迹象，而不是原因；没有必要测量血糖或血压。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- ارتفاع السكر والأسيتون ؟خطر والا ده الطبيعي ؟#ضياء_العوضي (打开来源)
- 发布日期
- 2025年12月23日
- 时间戳
- 0:28:42 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
- 所声称的机制
Lab values reflect adaptation, not disease.
- 所声称的健康影响
Abandoning monitoring
- 涉及人群
People with diabetes
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بيان فلسفه النظريه (打开来源)
- 发布日期
- 2026年2月14日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Measuring glucose and ketones is unnecessary/misleading.
2. 哪些内容可证实是正确的？
A single lab value should be interpreted in clinical context; treating numbers alone without regard to the person can cause harm (e.g. aggressive targets, C-INS-04). For people with type 2 diabetes who do not use insulin and are moderately controlled, routine daily finger-prick testing did not improve HbA1c or quality of life in a randomised trial (I-DIAB-111).
3. 哪些内容是错误或夸大的？
Glucose and ketone measurements identify DKA, hyperosmolar states and hypoglycaemia (I-INS-07, I-INS-08). ADA 2026: 'Individuals at risk for DKA should measure ketones in the presence of symptoms and potential precipitating factors' (I-INS-10). HbA1c predicts complications (I-INS-04).
4. 哪些内容仍不明确？
No data were found on how many followers stopped measuring glucose or blood pressure, or with what outcomes.
5. 哪些研究支持该说法？
None.
6. 哪些研究与该说法相矛盾？
I-INS-07, I-INS-08, I-INS-10, I-INS-04, I-DIAB-109 (blood ketone monitoring halved hospital/emergency visits), I-DIAB-110, I-DIAB-112 (BP lowering reduces death and stroke), I-DIAB-114, I-INS-133, I-INS-112.
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
糖尿病患者应继续监测血糖（并在有指征时监测酮体）。
评估详情
- 证据确定性的依据
Glucose and ketone monitoring is the basis for preventing and detecting hypoglycaemia and DKA; ADA recommends ketone measurement for people at risk. Ignoring measurements removes the main safety net.
- 来源质量
Own words, machine transcript.
- 地区可推广性
Universal.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: In people with diabetes, does measuring blood glucose, ketones and blood pressure improve outcomes compared with not measuring?
研究问题详解 (PICO)
- 人群
- People with type 1 and type 2 diabetes
- 干预或暴露
- Glucose, ketone and blood-pressure monitoring
- 对照
- No monitoring
- 地域范围
- universal biology
- 结局指标
- DKA/hospitalisation
- HbA1c
- Mortality and cardiovascular events (BP)
- Hypoglycaemia
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Daily finger-prick tests in type 2 diabetes without insulin
Young LA et al.. JAMA Intern Med 2017 · PMID 28600913 · DOI 10.1001/jamainternmed.2017.1233 随机对照试验已核查摘要新增Monitor Trial: routine daily finger-prick testing in non-insulin-treated T2D.
- 实际结果
- HbA1c difference -0.05% (-0.27 to 0.17); no QoL benefit.
- 方法学质量
- high (pragmatic RCT)
- 相关性
- direct for a narrow subgroup (T2D without insulin, moderate control)
- 局限
- Does not concern insulin users, ketones, HbA1c or BP.
哪些证据不支持该说法？
Checking blood ketones on sick days in young people with type 1 diabetes
Laffel LM et al.. Diabet Med 2006 · PMID 16492211 · DOI 10.1111/j.1464-5491.2005.01771.x 随机对照试验已核查摘要新增Blood ketone monitoring on sick days in young people with T1D.
- 实际结果
- Hospital/emergency visits 38 vs 75 per 100 patient-years.
- 方法学质量
- moderate (small RCT)
- 相关性
- direct
- 局限
- Small; P=0.05.
Lowering blood pressure in type 2 diabetes
Meta-analysis of BP lowering in T2D.
- 实际结果
- Per 10 mmHg: death RR 0.87 (0.78-0.96), stroke 0.73 (0.64-0.83).
- 方法学质量
- high (40 RCTs)
- 相关性
- direct (BP must be measured to be treated)
- 局限
- Fixed-effects.
International guideline on diabetic ketoacidosis
2024 hyperglycaemic crises consensus: glucose and ketone measurement define and guide DKA treatment.
- 实际结果
- Treated DKA mortality <1%.
- 方法学质量
- high (international consensus)
- 相关性
- direct
- 局限
- Consensus.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Glucose, ketone and BP measurement are necessary safety tools; routine daily self-testing is of limited value only for non-insulin-treated T2D.
为什么有些研究权重更大
Guidelines, RCT and meta-analytic evidence on ketones and BP outweigh a single null trial in a low-risk subgroup.
因果关系是否已确立？ 很可能 Monitoring enables treatment that has proven benefit (BP lowering, insulin adjustment, DKA treatment); monitoring itself is a tool.
仍存在的不确定性
Optimal frequency of self-testing in non-insulin T2D.
合理的结论
False as a general rule; dangerous for insulin users.
为什么研究结果看起来互相矛盾？
The Monitor Trial (I-DIAB-111) answers a different question (routine SMBG in non-insulin T2D) from ketone monitoring in insulin-deficient people (I-DIAB-109) or BP measurement (I-DIAB-112).
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- In Egypt, severe DKA at presentation is common in children (I-INS-115); early ketone measurement is especially relevant.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Rate ratio of hospital/emergency visits – About 0.51; CI not recomputable from abstract 已重新计算
- Relative vs absolute effect – RR 0.87 for death corresponds to an ARR of 3.16 per 1000 patient-years (reported) 无法根据已发表数据重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Hospitalisation/DKA and cardiovascular outcomes with vs without monitoring
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (monitoring as enabler of treatment)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD). - ADA: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026) · 原始文献
Rec 10.1: measure blood pressure at every routine visit or at least every 6 months; rec 10.2 (A): home BP monitoring for people with hypertension and diabetes. - ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · 原始文献
'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant. - NICE: NG17 Type 1 diabetes in adults (last updated 17 August 2022) (2022) · 原始文献
Basal-bolus insulin for all adults with T1D (1.7.1); ketone monitoring in sick-day rules (1.10.1); DKA: isotonic saline and IV insulin infusion (1.10.5-1.10.7). - NICE: NG18 Diabetes in children and young people (last updated 11 May 2023) (2023) · 原始文献
Basal-bolus insulin from diagnosis (1.2.18); blood ketone testing and sick-day rules (1.2.82-1.2.83); DKA is serious and needs urgent hospital IV fluids and insulin (1.4.6, 1.4.21); DKA can occur with normal glucose (1.4.3). - ADA/EASD/JBDS/AACE/DTS: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report (I-INS-07) (2024) · 原始文献
Insulin is 'the cornerstone of DKA management'; isotonic fluids 500-1,000 mL/h initially; potassium replacement; treated DKA mortality <1%; glucocorticoids can precipitate hyperglycaemia.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | "self-monitoring of blood glucose" AND "non-insulin" AND "type 2 diabetes" AND randomized AND JAMA Intern Med[ta] | 支持性证据 | 1 | |
| PubMed | 2026年10月26日 | (laboratory monitoring OR "glucose monitoring") AND diabetes AND (unnecessary OR "no benefit" OR overuse) AND randomized | 支持性证据 | 15 | |
| Europe PMC | 2026年10月26日 | ("self-monitoring of blood glucose") AND ("non-insulin" OR "not using insulin") AND (TITLE:"meta-analysis" OR TITLE:"systematic review") | 支持性证据 | 96 | |
| PubMed | 2026年10月26日 | (blood ketone OR beta-hydroxybutyrate) AND (sick day OR "sick-day") AND randomized | 反对性证据 | 5 | |
| PubMed | 2026年10月26日 | "self-monitoring of blood glucose" AND "type 1 diabetes" AND HbA1c AND frequency AND (registry OR exchange) | 反对性证据 | 15 | |
| Europe PMC | 2026年10月26日 | ("blood ketone" OR "ketone monitoring" OR "ketone testing") AND ("diabetic ketoacidosis") AND (prevention OR hospitalization OR admission) AND (type 1 diabetes) | 反对性证据 | 722 | |
| Europe PMC | 2026年10月26日 | "ketone" AND "diabetic ketoacidosis" AND ("sick day" OR "sick-day") AND (TITLE:"monitoring" OR TITLE:"ketone") | 反对性证据 | 19 | |
| PubMed | 2026年10月26日 | Emdin CA[au] AND "blood pressure lowering" AND diabetes AND JAMA[ta] | 反对性证据 | 1 | |
| PMC (publisher full text) | 2026年10月26日 | Fetched ADA Standards of Care 2026 sections 2, 6, 8, 10, 14, 16 at pmc.ncbi.nlm.nih.gov/articles/PMC12690183, PMC12690178, PMC12690172, PMC12690187, PMC12690182, PMC12690180 | 指南 | 6 | |
| Springer (publisher full text) | 2026年10月26日 | Fetched https://link.springer.com/article/10.1007/s00125-026-06833-z (ADA/EASD 2026 T1D consensus) | 指南 | 1 | |
| Guideline websites (NICE) | 2026年10月26日 | Fetched https://www.nice.org.uk/guidance/ng17/chapter/Recommendations and /ng18/chapter/Recommendations | 指南 | 2 |
核查深度如何？
13 项相关研究：6 项核查了全文（其中 1 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (高)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (高)
The claim's core (no need to measure glucose, ketones or blood pressure) is contradicted by guidelines and trial evidence. The new Monitor Trial adds a fair nuance for non-insulin T2D but does not change the verdict.
新来源: I-DIAB-109 I-DIAB-110 I-DIAB-111 I-DIAB-112 I-DIAB-114 I-INS-133 I-INS-112
通俗解释
血糖和酮体检测就像警示灯。它们能及早显示血糖何时危险地过高或过低，或者酸性物质何时正在积聚。不测量，就失去了在急症发生前采取行动的机会。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (12)
-
International guideline on diabetic ketoacidosis
Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin, fluids and potassium are the core treatment; with this, fewer than 1% of adults die.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Diagnosis and management of DKA and HHS in adults
- 研究是如何开展的？
International consensus report based on systematic examination of literature since 2009 (ADA, EASD, JBDS, AACE, DTS)
- 研究了多少人、动物或样本？
not applicable; Adults with diabetes
- 实际发现了什么？
Insulin is the cornerstone; glucocorticoids worsen hyperglycaemia.
- 观察到的效应有多大？
Mortality <1% with treatment
- 研究结果对日常生活意味着什么？
Ketoacidosis needs hospital treatment with insulin.
- 该研究有哪些局限？
Consensus, not trial
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
EASD and JBDS (UK) co-authored; directly applicable.
- 从该研究中明确不能得出什么结论？
Outcomes of untreated DKA quantitatively.
-
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1叙述性综述独立交叉核查全文，含结构化偏倚风险评估DKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Epidemiology, pathogenesis, diagnosis and management of DKA
- 研究是如何开展的？
Narrative expert review (Nature Reviews Disease Primers)
- 研究了多少人、动物或样本？
not applicable; Adults and children with diabetes
- 实际发现了什么？
DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
DKA is an emergency.
- 该研究有哪些局限？
Narrative expert review without systematic methods; one author has research support from insulin makers.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
International.
- 从该研究中明确不能得出什么结论？
Quantitative estimates.
-
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006指南 / 立场声明独立交叉核查已核查全文★ 关键研究Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
- 研究了多少人、动物或样本？
not applicable; People with diabetes
- 实际发现了什么？
Individual targets; do not stop basal insulin when not eating.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Moderate targets and safety rules.
- 该研究有哪些局限？
US-centred; Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with EASD guidance.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
How much long-term blood sugar matters (UKPDS 35)
Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405队列研究独立交叉核查已核查摘要★ 关键研究Each 1% lower HbA1c was linked to 21% fewer diabetes deaths and 37% fewer eye/kidney complications.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Relation of glycaemia over time to complications
- 研究是如何开展的？
Prospective observational analysis within UKPDS (UKPDS 35)
- 研究了多少人、动物或样本？
4,585 (3,642 for RR); UKPDS patients (white, Asian Indian, Afro-Caribbean)
- 实际发现了什么？
Graded risk with HbA1c, no threshold.
- 观察到的效应有多大？
-21% per 1% HbA1c
- 研究结果对日常生活意味着什么？
High sugar damages the body.
- 该研究有哪些局限？
Observational
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
That pushing HbA1c to normal is always safe.
-
Checking blood ketones on sick days in young people with type 1 diabetes
Laffel LM et al.. Diabet Med 2006 · PMID 16492211 · DOI 10.1111/j.1464-5491.2005.01771.x随机对照试验独立交叉核查已核查摘要★ 关键研究Young people who checked blood ketones when sick needed hospital or emergency care about half as often as those using urine strips.
Blood ketone monitoring halved hospital/emergency visits (38 vs 75 per 100 PY).
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare blood vs urine ketone testing.
- 研究是如何开展的？
Randomised trial.
- 研究了多少人、动物或样本？
123 young people.
- 实际发现了什么？
38 vs 75 hospital/emergency visits per 100 patient-years.
- 观察到的效应有多大？
Rate ratio about 0.51.
- 研究结果对日常生活意味着什么？
Measuring ketones helps avoid emergencies.
- 该研究有哪些局限？
Small; borderline P.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'no need to measure acetone'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot give exact size of benefit.
-
Checking blood sugar more often goes with better control in type 1 diabetes
Miller KM et al.. Diabetes Care 2013 · PMID 23378621 · DOI 10.2337/dc12-1770横断面研究独立交叉核查已核查摘要★ 关键研究Among 20,555 people with type 1 diabetes, those who checked blood sugar more often had lower HbA1c.
More frequent glucose checks associated with lower HbA1c in T1D.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Relate glucose testing frequency to HbA1c.
- 研究是如何开展的？
Registry analysis.
- 研究了多少人、动物或样本？
20,555 people.
- 实际发现了什么？
More checks, lower HbA1c.
- 观察到的效应有多大？
Not in abstract.
- 研究结果对日常生活意味着什么？
Measuring helps people on insulin manage diabetes.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'no need to measure glucose'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot prove causation.
-
Lowering blood pressure in type 2 diabetes
Emdin CA et al.. JAMA 2015 · PMID 25668264 · DOI 10.1001/jama.2014.18574Meta分析独立交叉核查已核查摘要★ 关键研究In 40 trials with 100,354 people, each 10 mmHg lower systolic pressure reduced deaths by 13% and strokes by 27%.
BP lowering reduces mortality (RR 0.87 per 10 mmHg) in T2D; requires measurement.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify benefits of BP lowering in T2D.
- 研究是如何开展的？
Meta-analysis of 40 RCTs.
- 研究了多少人、动物或样本？
100,354 people.
- 实际发现了什么？
Death RR 0.87, stroke 0.73 per 10 mmHg.
- 观察到的效应有多大？
ARR 3.16 deaths per 1000 patient-years.
- 研究结果对日常生活意味着什么？
Measuring and treating blood pressure protects people with diabetes.
- 该研究有哪些局限？
Fixed-effects model.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'no need to measure blood pressure'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot define the optimal BP target for every person.
-
US diabetes standards 2026: blood pressure
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358899 · DOI 10.2337/dc26-S010指南 / 立场声明独立交叉核查已核查全文★ 关键研究Blood pressure should be measured at every visit, and people with diabetes and hypertension should check it at home.
BP at every visit; home monitoring for hypertension (A).
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide CV risk care.
- 研究是如何开展的？
Guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Measure BP every visit.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Regular BP checks protect heart, brain and kidneys.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Contradicts C-DIAB-02.
- 研究结果是否适用于德国和欧洲？
European guidance agrees.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
European and US consensus 2026 on type 1 diabetes in adults
Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z指南 / 立场声明独立交叉核查已核查全文★ 关键研究Lifelong insulin is essential in type 1 diabetes, and everyone with type 1 diabetes should be able to test glucose and ketones.
All people with T1D need glucose and ketone testing supplies.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Update guidance on adult T1D care.
- 研究是如何开展的？
Consensus report.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Insulin lifelong and essential; ketone testing for all.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
People with type 1 diabetes must never stop insulin.
- 该研究有哪些局限？
Consensus.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
European (EASD) guidance.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Fasting, lack of water and ketoacidosis in type 1 diabetes
Burge MR et al.. Metabolism 2001 · PMID 11229425 · DOI 10.1053/meta.2001.20194其他独立交叉核查已核查摘要★ 关键研究When insulin was stopped, prior fasting lowered blood sugar but made ketones and acid build up faster; lack of water raised both sugar and ketones.
Glucose can be lower during fasting while ketoacidosis progresses; ketone measurement is needed.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Study how fasting and dehydration influence DKA development.
- 研究是如何开展的？
Short insulin withdrawal experiments.
- 研究了多少人、动物或样本？
25 adults with T1D.
- 实际发现了什么？
Fasting: lower glucose but faster ketosis; dehydration: higher glucose and faster ketosis.
- 观察到的效应有多大？
Not given in abstract.
- 研究结果对日常生活意味着什么？
Fasting can hide danger: sugar falls while acid rises.
- 该研究有哪些局限？
Small study.
- 它对 Elawady 的具体说法说明了什么？
Contradicts dry fasting as DKA treatment.
- 研究结果是否适用于德国和欧洲？
Universal physiology.
- 从该研究中明确不能得出什么结论？
Cannot give clinical outcome rates.
-
NICE guideline NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
National Institute for Health and Care Excellence (NICE). NICE guideline 2015指南 / 立场声明独立交叉核查已核查全文★ 关键研究UK paediatric guideline: insulin from diagnosis; DKA needs urgent hospital IV fluids and insulin; honeymoon phase is temporary.
Blood ketone testing and sick-day rules.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
National guidance.
- 研究是如何开展的？
Evidence-based guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Rec 1.2.18: offer children and young people with T1D a multiple daily injection basal-bolus insulin regimen from diagnosis. Recs 1.2.82-1.2.83: sick-day rules including blood ketone monitoring; offer blood ketone strips and meter. Rec 1.4.3: children taking insulin may develop DKA with normal blood glucose. Rec 1.4.6: explain that DKA is serious and needs urgent hospital assessment. Rec 1.4.21: treat DKA with intravenous fluids and intravenous insulin if the child is not alert, nauseated/vomiting or clinically dehydrated. Rec 1.2.25: explain the partial remission ('honeymoon') phase with low insulin needs.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
UK paediatric guideline: insulin from diagnosis; DKA needs urgent hospital IV fluids and insulin; honeymoon phase is temporary.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Contradicts insulin-free management.
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Ketoacidosis during very-low-carbohydrate diets
Roberts CGP et al.. Diabetes Obes Metab 2025 · PMID 39996364 · DOI 10.1111/dom.16252队列研究独立交叉核查已核查摘要★ 关键研究DKA was rare (about 1 per 1000 patient-years in type 2 diabetes) in a supervised programme, but almost three times higher with SGLT2 inhibitors.
Authors recommend home ketone monitoring to manage DKA risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure ketosis-related illness on ketogenic diets.
- 研究是如何开展的？
Retrospective programme data.
- 研究了多少人、动物或样本？
72,751 patient-years.
- 实际发现了什么？
DKA 1.01/1000 PY in T2D; 2.90 with SGLT2 inhibitors.
- 观察到的效应有多大？
Rates as reported.
- 研究结果对日常生活意味着什么？
Diet changes in diabetes need medical supervision and ketone checks.
- 该研究有哪些局限？
Programme data; no T1D.
- 它对 Elawady 的具体说法说明了什么？
Supports supervision and monitoring, not stopping medicines alone.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot address type 1 diabetes.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Daily finger-prick tests in type 2 diabetes without insulin
Young LA et al.. JAMA Intern Med 2017 · PMID 28600913 · DOI 10.1001/jamainternmed.2017.1233随机对照试验独立交叉核查已核查摘要★ 关键研究For people with type 2 diabetes not using insulin, daily self-testing did not improve HbA1c or quality of life over one year.
Routine SMBG did not help non-insulin-treated T2D; does not apply to insulin users, ketones or BP.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test routine SMBG in non-insulin T2D.
- 研究是如何开展的？
Pragmatic RCT.
- 研究了多少人、动物或样本？
450 patients.
- 实际发现了什么？
No HbA1c difference.
- 观察到的效应有多大？
-0.05% (-0.27 to 0.17).
- 研究结果对日常生活意味着什么？
Routine self-testing is not always needed in type 2 diabetes without insulin; regular HbA1c checks still are.
- 该研究有哪些局限？
Moderately controlled patients only.
- 它对 Elawady 的具体说法说明了什么？
Supports a narrow kernel; not 'no measurement at all'.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot justify stopping monitoring in insulin users.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
错误 监测血糖和酮体能预防急症；放弃监测是危险的。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Hyperglycemic Crises in Adults With Diabetes: A Consensus Report.. Umpierrez GE et al.. Diabetes Care 2024 · PMID 39052901 · DOI 10.2337/dci24-0032
- Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.. Stratton IM et al.. BMJ 2000 · PMID 10938048 · DOI 10.1136/bmj.321.7258.405
- Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial.. Laffel LM et al.. Diabet Med 2006 · PMID 16492211 · DOI 10.1111/j.1464-5491.2005.01771.x
- Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants.. Miller KM et al.. Diabetes Care 2013 · PMID 23378621 · DOI 10.2337/dc12-1770
- Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.. Emdin CA et al.. JAMA 2015 · PMID 25668264 · DOI 10.1001/jama.2014.18574
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358899 · DOI 10.2337/dc26-S010
- The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
- Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis.. Burge MR et al.. Metabolism 2001 · PMID 11229425 · DOI 10.1053/meta.2001.20194
- NICE guideline NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015
- Illnesses associated with ketosis including diabetic ketoacidosis during very low carbohydrate and ketogenic diets.. Roberts CGP et al.. Diabetes Obes Metab 2025 · PMID 39996364 · DOI 10.1111/dom.16252
- Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial.. Young LA et al.. JAMA Intern Med 2017 · PMID 28600913 · DOI 10.1001/jamainternmed.2017.1233